Timothy Kubal

740 total citations
27 papers, 403 citations indexed

About

Timothy Kubal is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Timothy Kubal has authored 27 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Public Health, Environmental and Occupational Health and 8 papers in Economics and Econometrics. Recurrent topics in Timothy Kubal's work include Economic and Financial Impacts of Cancer (8 papers), Neutropenia and Cancer Infections (6 papers) and Acute Myeloid Leukemia Research (5 papers). Timothy Kubal is often cited by papers focused on Economic and Financial Impacts of Cancer (8 papers), Neutropenia and Cancer Infections (6 papers) and Acute Myeloid Leukemia Research (5 papers). Timothy Kubal collaborates with scholars based in United States and South Africa. Timothy Kubal's co-authors include Lubomir Sokol, Elizabeth M. Sagatys, Samir Dalia, Asmita Mishra, Ronald S. Winokur, Dori Klemanski, Catherine Liu, Pelin Cinar, Dan Liu and Rafaël Fonseca and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Timothy Kubal

25 papers receiving 390 citations

Peers

Timothy Kubal
R. Babela Slovakia
María Jesús Téllez Spain
Stella Bowcock United Kingdom
Flavia M. Facio United States
Kelsey K. Baker United States
Géraldine Dahlqvist Belgium
Justice Clark United States
Staci D. Arnold United States
Hollie Schmidt United States
Graham McIlroy United Kingdom
R. Babela Slovakia
Timothy Kubal
Citations per year, relative to Timothy Kubal Timothy Kubal (= 1×) peers R. Babela

Countries citing papers authored by Timothy Kubal

Since Specialization
Citations

This map shows the geographic impact of Timothy Kubal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Kubal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Kubal more than expected).

Fields of papers citing papers by Timothy Kubal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Kubal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Kubal. The network helps show where Timothy Kubal may publish in the future.

Co-authorship network of co-authors of Timothy Kubal

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Kubal. A scholar is included among the top collaborators of Timothy Kubal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Kubal. Timothy Kubal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patil, Nanasaheb M., et al.. (2025). Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review. eJHaem. 6(4). e70094–e70094.
2.
Krause, Diana N., Anne Gross, Daniel Mulkerin, et al.. (2022). Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network’s Member Institutions. Journal of the Advanced Practitioner in Oncology. 13(5). 507–513. 2 indexed citations
3.
Kubal, Timothy, et al.. (2022). Worsening hypereosinophilia with use of dupilumab. Annals of Allergy Asthma & Immunology. 130(3). 272–275. 1 indexed citations
4.
Shulman, Lawrence N., Ephraim P. Hochberg, Anne C. Chiang, et al.. (2022). COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. Journal of the National Comprehensive Cancer Network. 20(13). 1–4. 4 indexed citations
5.
Mason, Neil, Julio M. Pow‐Sang, Robert A. Gatenby, et al.. (2021). Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer.. PubMed. 14(1). 15–20. 10 indexed citations
6.
Cinar, Pelin, Timothy Kubal, Alison G. Freifeld, et al.. (2020). Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe. Journal of the National Comprehensive Cancer Network. 18(5). 504–509. 79 indexed citations
7.
Kubal, Timothy, et al.. (2019). National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers. Journal of Oncology Practice. 15(5). e458–e466. 18 indexed citations
8.
9.
Hicks, J. Kevin, Rami S. Komrokji, Timothy Kubal, et al.. (2019). Prospective CYP2C19‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clinical Pharmacology & Therapeutics. 107(3). 563–570. 34 indexed citations
10.
Colonna, Sarah V., John Sweetenham, Trever Burgon, et al.. (2018). A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clinical Breast Cancer. 19(2). e376–e384. 4 indexed citations
11.
Kubal, Timothy, Rami S. Komrokji, David A. Sallman, et al.. (2018). Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML.. Journal of Clinical Oncology. 36(15_suppl). e19013–e19013. 4 indexed citations
12.
Hicks, J. Kevin, Rami S. Komrokji, Timothy Kubal, et al.. (2018). CYP2C19-guided voriconazole prophylaxis in neutropenic AML patients.. Journal of Clinical Oncology. 36(15_suppl). 6594–6594. 1 indexed citations
13.
14.
Komrokji, Rami S., Kendra Sweet, Najla H. Al Ali, et al.. (2016). Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double‐induction chemotherapy: Analysis from a large, single institution experience. American Journal of Hematology. 92(3). 232–237. 11 indexed citations
15.
Kubal, Timothy, et al.. (2015). Using Vignettes to Measure and Encourage Adherence to Clinical Pathways in a Quality-Based Oncology Network: An Early Report on the Moffitt Oncology Network Initiative.. PubMed. 24(10). 56–64. 4 indexed citations
16.
17.
Dalia, Samir, Elizabeth M. Sagatys, Lubomir Sokol, & Timothy Kubal. (2014). Rosai-Dorfman Disease: Tumor Biology, Clinical Features, Pathology, and Treatment. Cancer Control. 21(4). 322–327. 153 indexed citations
18.
Kubal, Timothy & Jeffrey E. Lancet. (2013). The thorny issue of relapsed acute myeloid leukemia. Current Opinion in Hematology. 20(2). 100–106. 3 indexed citations
19.
Kim, Richard D. & Timothy Kubal. (2011). To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 85–87. 1 indexed citations
20.
Winokur, Ronald S., Timothy Kubal, Dan Liu, Scott Francis Davis, & Bret N. Smith. (2004). Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy. Epilepsy Research. 58(2-3). 93–105. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Babela Breakdown of academic impact, for papers by María Jesús Téllez Breakdown of academic impact, for papers by Stella Bowcock Breakdown of academic impact, for papers by Flavia M. Facio Breakdown of academic impact, for papers by Kelsey K. Baker Breakdown of academic impact, for papers by Géraldine Dahlqvist Breakdown of academic impact, for papers by Justice Clark Breakdown of academic impact, for papers by Staci D. Arnold Breakdown of academic impact, for papers by Hollie Schmidt Breakdown of academic impact, for papers by Graham McIlroy
Rankless by CCL
2026